Navigation Links
Major statin study reveals several important findings for reducing prostate cancer and disease
Date:4/25/2009

ROCHESTER, Minn. -- Statins, drugs widely prescribed to lower cholesterol, may have protective effects on prostate health. This large Mayo Clinic cohort study looked at three different aspects of urological health -- prostate cancer, erectile dysfunction and prostate enlargement. Initial research results are being presented April 25-30, 2009, at the American Urological Association (AUA) meeting in Chicago.

    VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Drs. St. Sauver, Karnes and Breau describing the research, are available on the Mayo Clinic News Blog,. These materials are also subject to embargo, but may be accessed in advance by journalists for incorporation into stories. The password for this post is password Statin049.

These Mayo Clinic study findings came from data in the Olmsted County Study of Urinary Health Status among Men, a large cohort study of men living in Olmsted County, Minn. This study has followed 2,447 men ages 40 to 79 from 1990 to the present to assess various urologic outcomes among aging men.

"One of the major advantages of this large cohort study is that the men have participated in this study for over 15 years. Because of this, we have the ability to look at associations between statin use, how long statins were used and multiple aspects of urologic function," says Jennifer St. Sauver, Ph.D., Mayo Clinic epidemiologist and study author.

Three significant abstracts are being presented at the AUA meeting:

Statins May Reduce Risk of Prostate Cancer (April 26, 3:30-5:30 p.m. CDT)

In the first study, researchers followed the 2,447 men for over 15 years and discovered that men taking statins were less likely to develop prostate cancer, compared to men who did not take statins.

Of the statin users, 38 (6 percent) were diagnosed with prostate cancer. Comparatively, non-statin users were three times more likely to develop prostate cancer, suggesting statin use may prevent development of prostate cancer.

"In recent years, it has been suggested that statin medications may prevent development of cancer. However, until now, there has been limited evidence to support this theory," says Rodney Breau, M.D., a Mayo Clinic urologic oncology fellow who led the study. "Our research provides evidence that statin use is associated with a threefold reduced risk of being diagnosed with prostate cancer."

Statin medications are currently used to lower cholesterol or to help prevent heart attack and stroke in high-risk patients. In the laboratory setting, researchers have observed that statin medications prevent cancer cells from dividing and, in fact, may cause some cancer cells to die.

"In the United States, one in six men will develop prostate cancer; however, far more will develop heart disease," says Jeffrey Karnes, M.D., Mayo Clinic urologist and senior author on the study. "I tell my patients to take care of their heart because what's good for the heart is also good for the prostate."

The investigators emphasize that these results are preliminary. To determine if statins are protective for prostate cancer, randomized controlled trials are necessary, says Dr. Karnes.

Statin Use May Protect Against Erectile Dysfunction (April 27, 10:30 a.m.-12:30 p.m. CDT)

Hyperlipidemia, high cholesterol and other risk factors for heart disease have been shown to put men at risk for erectile dysfunction (ED). With this in mind, Mayo Clinic researchers studied 1,480 men from the Olmsted County cohort to determine if men who used statins were less likely to develop erectile dysfunction, compared to men who did not use statins.

Overall, statin use was not significantly associated with a decreased risk of developing ED. However, statins were associated with a decreased risk of ED among older men (>60 years). Men in this age category who used statins were less likely to develop ED, compared to older men who did not use statins. Additionally, men who took statins for a longer time were more protected against developing ED. For example, men who took statins for nearly nine years or more were 64 percent less likely to develop ED, while men who took statins for less than three years had about the same risk of developing ED. compared to men who did not take statins.

"Protection of vascular health remains an important concomitant of preserving erectile health. Our data suggest that longer use of statins may result in the lowest risk of erectile dysfunction," says Ajay Nehra, M.D. , Mayo Clinic urologist and senior study author.

ED is common, and prevalence increases with age. It affects 5 to 10 percent of men at age 40. By age 70, from 40 to 60 percent of men have the condition.

Statin Use May Prevent Prostate Enlargement (April 28, 1:00-3:00 p.m. CDT)

Benign prostatic enlargement affects one in four men ages 40 to 50 and almost half of 70- to 80-year-old men. The condition is most often diagnosed when men visit their physicians due to urinary problems prompted by prostate enlargement. Mayo Clinic researchers have found that taking statins may prevent or delay benign prostatic enlargement.

Of the 2,447 men studied, 729 (30 percent) were statin users; researchers found that statin users were 63 percent less likely to develop lower urinary tract problems and 57 percent less likely to develop an enlarged prostate.

"Statins have been shown to have anti-inflammatory effects, and previous research suggests inflammation may be associated with benign prostate disease," says Dr. St. Sauver. "This study suggests that men's urinary health could be improved by taking statin medications."

Further Study Needed

The researchers note that further studies, particularly clinical trials, are necessary to determine whether taking statins might prevent development of this common condition.

"If you are taking a statin for a heart condition or to lower cholesterol, these studies suggest that statins could have other benefits," says Dr. St. Sauver. "However, it's very clear we need more information before men are advised to start taking statins for their urological health."


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Laboratory at UI plays major role in diagnosing cancer
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Major grant advances UWs clinical and translational research enterprise
7. Major differences revealed in how local authorities in the UK support disabled people
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology: